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The biological activities of several ovine chorionic somatomammotropin (oCS) derivatives obtained by 
chemical modification of the lysine residues were studied by radioreceptor assays using rabbit mammary 
homogenates (lactogenic activity, L.A.) and liver homogenates (somatotropic activity, S.A.). Even if the 
control treatment with BHI markedly decreased the L.A., it was clear that methylation mainly affected 
the S.A. and that ethylation reduced both activities. Guanidination inactivated almost completely both 
activities and acetimidination at a very low degree (3 of 14 lysines) led to less than 50% of both activities. 
These results show the involvement of lysine residues in the interaction of oCS with lactogenic and 
somatotropic receptors. 
Ovine chorionic somatomammotropin Prolactin Growth hormone Lysine residue Receptor 
1. INTRODUCTION 
Structurally, placental lactogenic hormones 
[placental lactogen (PL) or chorionic somatomam- 
motropin (CS)] are located between prolactins and 
growth hormones and exhibit special physiological 
characteristics. In ruminants, these hormones have 
both lactogenic and growth hormone activities 
[l-3]. In other species, e.g. rat and mouse, only 
lactogenic activity has been demonstrated [2,4]. In 
the human female, human chorionic somatomam- 
motropin (hCS) is almost unable to bind to growth 
hormone receptors [5], which raises some ques- 
tions concerning the physiological role of this hor- 
mone. Furthermore, some mammals seem to lack 
any CS-like hormone [6-81. The oCS, endowed 
with both lactogenic and somatotropic action, is a 
very interesting molecule for studying relationships 
between chemical structure and biological activity. 
Purification and physicochemical characterization 
of oCS have recently been performed [9,12]. The 
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amino acid sequence of this molecule is still 
unknown. The only known sequence in the family 
of CS is that of hCS, but this molecule shows ex- 
clusively prolactin activity despite a very close 
homology of its chemical structure with hGH 
[13,14]. 
It was of interest to investigate the effect of 
chemical modification of oCS on its binding to 
somatotropic and lactogenic receptors. As the 
basic residues might be involved in specific binding 
of hormones to receptors, we first studied the ef- 
fect of modification of the hormonal lysine 
residues on their binding to liver somatotropic 
receptors and to mammary prolactin receptors. 
Four different modifications were performed: 
methylation of the amino groups which is accom- 
panied by a slight change in the pK; ethylation 
which introduces a longer alkyl chain and the 
possibility of considerable steric hindrance at the 
interface between the hormone and the receptor; 
guanidination which modifies the pK and the 
distance between the charge and the polypeptide 
backbone; and acetimidination with the same ef- 
fect, but more marked. 
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2. MATERIALS AND METHODS 2.3. Radioreceptor assay of lactogenic and growth 
2.1. Purification of 0CS 
activities 
2.3.1. Lactogenic activity 
Purification was performed as in [10,12]. oCS 
was purified about lOOO-fold and was not con- 
taminated by either prolactin or growth hormone. 
Its activity estimated by radioreceptor assay was 
equivalent o 20 IU/mg NIH ovine prolactin stan- 
dard and to 0.8 IU/mg NIH bovine growth 
hormone. 
The amino acid composition was established us- 
ing a Technicon Autoanalyzer. The content of 
lysine for an M, of 22000 was 14 residues. 
2.2. Chemical modifications 
2.2.1. Reductive alkylation 
Reductive methylation and ethylation were car- 
ried out by addition of sodium borohydride and 
formaldehyde or acetaldehyde to ocs 
(0.5-1.0 mg) dissolved in borate buffer (pH 9) as 
in [ 151. The solutions were dialyzed against a 
pyridine solution (1%) and freeze-dried. Deter- 
minations of lysine, methyl- and ethyllysine were 
made using a Technicon autoanalyzer and elution 
gradients containing isopropanol [15,16]. A blank 
for biological assays was prepared by treating hor- 
mone with borohydride and borate buffer (pH 9, 
no added aldehyde). 
This activity was measured as in [lo]. 
Mammary gland membranes were obtained 
from rabbits treated on day 10 of lactation with 
2_cY-bromocryptine (CB 154, Sandoz, 2 mg twice 
daily for 2 days) to desaturate their receptors. The 
standard curve was established by incubation of 
membrane receptors, radioiodinated prolactin and 
different concentrations of unlabelled ovine pro- 
lactin (NIH-PS-7,24 IU/mg) for 5 h at 21°C. Lac- 
togenic activity of modified hormones was deter- 
mined by adding these hormone derivatives to the 
incubation medium instead of the unlabelled pro- 
lactin. The specificity of the assay was checked: 
only hormones with lactogenic activity in the rab- 
bit (prolactins of different species, placental lac- 
togens and human growth hormone) are able to 
compete with ovine prolactin at the rabbit mam- 
mary receptor sites. The rabbit receptor exhibits 
less strict specificity than the ovine receptor. 
2.3.2. Growth hormone activity 
2.2.2. Guanidination 
This reaction was performed using 0.3 M O- 
methylisourea sulfate (Aldrich, Europe) at pH 10.3 
and 5°C (0.7 mg oCS/O.lS ml) for two periods, 
24 h and 5 days. At the end of the reaction, the 
solutions were dialyzed against pyridine solutions. 
After 1 day of reaction, the solution became slight- 
ly opalescent. In both cases, the solutions were 
centrifuged and the precipitate discarded. The 
degree of guanidination was measured by amino 
acid analysis. A blank was prepared by treatment 
of the hormone at pH 10.4 for 5 days at 5°C. 
This activity was determined by radioreceptor 
assay [5] with membranes of rabbit liver on day 17 
of pregnancy in the presence of ‘251-labelled 
Pentex bovine growth hormone (bGH) and stan- 
dard unlabelled bGH (Pentex, 1 IU/mg). In rab- 
bit, the liver is particularly rich in GH receptors 
and poor in prolactin receptors. Each sample was 
tested several times in duplicate at various dilu- 
tions in the following buffer: 25 mM Tris (pH 7.6), 
10 mM MgClz, bovine serum albumin 0.1% (w/v). 
3. RESULTS AND DISCUSSION 
2.2.3. Acetimidination 
To obtain a low degree of chemical modifica- 
tion, this reaction was performed at a low concen- 
tration of reagent (ethylacetimidate hydrochloride, 
Aldrich) for 24 h, at pH 10 and 5°C. Determina- 
tion of the e-acetimidyllysine was performed by 
amino acid analysis as in [ 171. 
Table 1 lists the relative potencies expressed in 
terms of native oCS (percentage). These values 
were calculated by comparison of the hormone 
concentration needed for 50% inhibition of 
specific binding. Amino acid analysis of oCS 
prepared in our laboratory showed a lysine content 
similar to that reported in [ 181. The results obtain- 
ed in the radioreceptor assay for lactogenic activity 
are reported in fig. 1 and those from a similar assay 
for somatotropic activity in fig.2. 
Treatment of oCS with borohydride at 0°C and 
pH 9 (conditions necessary for alkylation of amino 
groups) caused a slight loss in the binding activity 
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Relative potencies of oCS derivatives in terms of native oCS in the lactogenic and somatotropic radioreceptor assays 
Treatments Native oCS Control Methylation Ethylation 
(pH 9, BH;, (Met-oCS) (Et-oCS) 
1 h) 
(Red-oCS) 
Modified 
lysine 
residues (vo) 0 0 75 (lo)= 55 (8)a 
Lactogenic 
binding 
activity (vo) 100 45.5 38.5 10 
Somatotropic 
binding 
activity (4/o) 100 94 7.5 36.5 
a Number of modified lysine residues out of the 14 residues found 
Control Guanidination Acetimidin- 
(PH 10, (Gu-oCS) ation 
4.5 days, (24 h) (Am-oCS) 
4°C) 
0 81 (ll)a 20 (3)a 
100 1 29.5 
100 1.5 64 
Relative potencies expressed as a percentage of the binding activity of native oCS calculated by comparison of the 
hormone concentration needed for 50% inhibition of specific binding 
of the molecule to somatotropic receptors (table 
1). The loss was much larger for lactogenic recep- 
tors. We observed that this treatment also 
drastically reduced the biological activity of ovine 
prolactin as a consequence of the reduction of 
some disulfide bridges and subsequent inter- 
molecular rearrangements (unpublished). 
Fig. 1. Specific binding of native and modified oCS in a Fig.2. Specific binding of native and modified oCS in a 
radioreceptor assay for lactogenic activity with lactating radioreceptor assay for somatotropic activity with 
rabbit mammary membranes. oCS activity is expressed pregnant rabbit liver membranes. oCS activity is 
in ovine prolactin equivalents (NIH PS 7, 24 IU/mg) expressed in bovine growth hormone equivalents (bGH 
(A----A); Red-oCS, reduced oCS (A----A); Met-oCS, Pentex, 1 IU/mg) (s); Red-oCS, reduced oCS 
methylated oCS (U--O); Am-oCS, acetiminidylated (A--+); Met-oCS, methylated oCS (U-U); Am-oCS, 
oCS (H); Et-oCS, ethylated oCS (m); Gu-oCS, acetiminidylated oCS (H); Et-oCS, ethylated oCS 
guanidinated oCS (M). (c--o); Gu-oCS, guanidinated oCS (M). 
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3.1. Methylation 
The least disturbing chemical modification 
which can be introduced into the amino groups on- 
ly slightly reduced the lactogenic activity below the 
level observed in the blank (treated at pH 9 with 
borohydride) despite the high degree of modifica- 
tion (75% of lysine residues) (table 1). However, 
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partial loss of the binding activity with regard to 
lactogenic receptors resulting from methylation of 
oCS might be masked by the considerable loss of 
activity due to disturbance of the conformation 
caused by reduction of disulfide bridges. In con- 
trast, the somatotropic activity was clearly reduced 
suggesting more intimate involvement of the 
amino acid groups in binding of the hormone to its 
somatotropic receptors. That the binding to 
somatotropic receptors of oCS treated with 
borohydride is only slightly decreased suggests that 
the growth hormone activity is less dependent on 
the secondary and tertiary structure than is lac- 
togenic activity. That may be due to the fact that 
the somatotropic activity is more strictly located. 
As methylation of the amino groups produced only 
a very slight change in pK [15], the drastic loss of 
binding activity of oCS to somatotropic receptors 
after methylation must be attributed to steric hin- 
drance resulting from the introduction of methyl 
groups on f-NHz. Thus, some lysine residues ap- 
pear to be essential for the growth hormone activi- 
ty of ocs. 
3.2. Ethylation 
Ethylation, which may be the cause of steric hin- 
drance around the amino groups, decreased the 
binding activity of the molecule to both lactogenic 
and somatotropic receptors (table 1; fig.l,2). The 
degree of ethylation was, as usual, lower than that 
of methylation which certainly explains the higher 
somatotropic activity of the ethylated derivative 
compared to the methylated one. 
Treatment of oCS at pH 10.4 and 4°C 
(necessary for guanidination or acetimidination) 
even for 5 days is apparently without effect on the 
biological activity. The consequences of 
guanidination on the biological activity are thus 
more clearly shown: both lactogenic and 
somatotropic activities were almost completely 
abolished confirming the disturbing character of 
this chemical modification. Acetimidination, even 
at a very low degree (3 residues out of 14), caused 
a decrease of -50% in both activities. 
Accordingly, it may be concluded that the lysine 
residues are involved in the binding of oCS to both 
types of receptors. This involvement appears more 
marked in the case of somatotropic receptors since 
these receptors appear to be unable to recognise 
the methylated oCS which is active in regard to the 
lactogenic receptors. As yet, identification of these 
essential residues cannot be made as the amino se- 
quence in oCS remains unknown. But, according 
to previous studies [19,20] on the relationship bet- 
ween structure and biological activity in other 
growth hormones, we may locate these essential 
lysine residues in the N-terminal segment contain- 
ing two-thirds of the amino acid sequence. 
However, it may be assumed that the absence of 
somatotropic activity of certain placental actogens 
results from a mutation in the nucleotide coding of 
some lysine residues. 
Chemical modification of lysine residues of 
other hormones endowed with prolactin or GH ac- 
tivities also decreases their biological activity (un- 
published). Mostly, the loss of activity is much 
larger for the somatotropic activity of these 
hormones. 
A decrease in biological activity following 
chemical modification of the lysine residues has 
been reported for other hormones. However, the 
consequences of such modifications may vary con- 
siderably depending on the nature of the introduc- 
ed modification or on the structure of the protein, 
even for phylogenetically related molecules uch as 
LH and FSH. Methylated luteinizing hormone is 
quite active [16,21] but methylated FSH is inactive 
[22]. Ethylated and guanidinated luteinizing hor- 
mone are less active than the native hormone and 
the fully acetimidinated molecule is inactive 
[16,23,24]. Large losses of biological activity have 
also been observed after modification of amino 
groups in PMSG and glucagon [25,26]. A selective 
loss of activity has been observed occasionally: 
guanidinated LH is able to bind to the rat Leydig 
cell receptors without stimulation of 
steroidogenesis [27]. 
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